ArticleAmerican journal of translational research2025
Adjuvant therapy guided by molecular classification in endometrial cancer: survival benefit and safety profile.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the effect of molecular classification-based postoperative adjuvant therapy on survival outcomes and treatment safety in patients with endometrial cancer.
methodsThis retrospective study included 208 endometrial cancer patients treated between January 2022 and January 2025. Patients were divided into a control group (n = 102), receiving conventional adjuvant therapy, and an observation group (n = 106), receiving molecular classification-based personalized regimens. The primary endpoints were disease-free survival (DFS) and overall survival (OS). Secondary measures included objective response, treatment-related toxicity, treatment delivery factors, patient-reported outcomes, and next-generation sequencing of circulating tumor DNA (ctDNA). Multivariate Cox regression was used to explore molecular subtypes and clinicopathologic predictors of 5-year DFS.
resultsIn the observation group, immune therapy was exclusively administered, and treatment regimens significantly differed from the control group, which received chemoradiotherapy. The observation group showed significantly better DFS (HR = 0.52, 95% CI 0.30-0.89, P = 0.01) and OS (HR = 0.45, 95% CI 0.21-0.95, P = 0.03). Molecular subtype analysis indicated better prognosis for POLE-ultramutated tumors and poorer prognosis for p53-abnormal tumors. The observation group had fewer adverse events (grade ≥ 2: 38.7% vs. 63.7%, P = 0.001) and higher objective response rates (65.1% vs. 43.1%, P = 0.001).
conclusionsMolecular classification-based adjuvant therapy improved survival, response rates, and ctDNA clearance with fewer toxicities. These findings support incorporating molecular classification into postoperative treatment to enhance outcomes in endometrial cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.